Clinical trials: Myelosuppression, open to volunteers
Acute Myeloid Leukemia, Neutropenia
UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia
The purpose of the study is to explore the safety and efficacy of UCMSC-Exo in consolidation chemotherapy-induced myelosuppression in patients with acute myeloid leukemia after achieving complete remission.
- Conditions
- Acute Myeloid Leukemia, Neutropenia, Anemia, Thrombocytopenia
- Trial name
- NCT06245746
- Testing
- umbilical cord derived mesenchymal stem cells exosomes (UCMSC-Exo)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lung Cancer, Small Cell
Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin
This prospective, randomized, controlled phase II study aims to evaluate the efficacy of combination therapy with Envafolimab and chemotherapy in first-line extensive stage SCLC, as well as the impact of Trilaciclib on the…
- Trial name
- NCT06698965
- Testing
- Chemotherapy （Etoposide and Carboplatin）, Immunotherapy （Envafolimab）, Trilaciclib
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Shanghai Chest Hospital
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR
Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
This study is a prospective, single arm phase II clinical trial aimed at patients with advanced non-small cell lung cancer resistant to EGFR-TKI.
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), EGFR, Myelosuppression
- Trial name
- PROTECT-2 (NCT06992739)
- Testing
- Trilaciclib and Sacituzumab Tirumotecan
- Where
- China
- Volunteers
- 49 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor
Outcomes of Early and Late Administration G-CSF for Primary Prophylaxis in Non-Hodgkin's Lymphoma Patients
The goal of this clinical trial is to Primary Objectives: 1. To compare the incidence of febrile neutropenia in patients with non-Hodgkin's lymphoma who received early or late granulocyte colony-stimulating factor (G-CSF) during…
- Conditions
- Non-Hodgkin's Lymphoma (NHL), Granulocyte Colony Stimulating Factor, Febrile Neutropenia (FN), Myelosuppression Adult
- Trial name
- G-CSF in NHL (NCT06665737)
- Testing
- Early receiving G-CSF group, Late receiving G-CSF group
- Where
- 3 sites in Thailand
- Volunteers
- 126 people
- Sponsor
- Department of Medical Services Ministry of Public Health of Thailand
Nasopharyngeal Carcinoma, Leucogen
A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
Toxic and side effects during and after chemoradiotherapy for nasopharyngeal carcinoma seriously affect patients' treatment compliance and long-term quality of life.
- Conditions
- Nasopharyngeal Carcinoma, Leucogen, Chemotherapy, Myelosuppression
- Trial name
- NCT05780294
- Testing
- 5-fu, Lobaplatin, leucogen
- Where
- China
- Volunteers
- 132 people
- Sponsor
- Sun Yat-sen University
Non-Small Cell Lung Cancer, Myelosuppression
Trilaciclib in Combination With Docetaxel for Second-Line and Beyond Treatment of Locally Advanced or Metastatic NSCLC
This study is a prospective, single arm phase II study aimed at patients with locally advanced or metastatic non-small cell lung cancer undergoing second-line or beyond treatment.
- Trial name
- PROTECT-1 (NCT06929936)
- Testing
- Trilaciclib combined with Docetaxel
- Where
- China
- Volunteers
- 33 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Head and Neck Squamous Cell Carcinoma (HNSCC)
Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This prospective, single-arm, exploratory, phase II study was designed to evaluate the efficacy and safety of Trilaciclib in reducing chemotherapy-induced neutropenia in patients with recurrent or metastatic head and neck…
- Trial name
- NCT06714266
- Testing
- Trilaciclib
- Volunteers
- 30 people
- Sponsor
- Shandong Cancer Hospital and Institute
Nasopharyngeal Carcinoma (NPC), Myelosuppression
Dynamic Risk Prediction of Severe Myelosuppression in Nasopharyngeal Carcinoma
This multicenter, prospective, observational cohort study aims to evaluate a previously developed dynamic risk prediction model for severe treatment-related myelosuppression in patients with nasopharyngeal carcinoma receiving…
- Trial name
- NCT07819656
- Where
- China
- Volunteers
- 1,782 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Bone Marrow Suppression
Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression .
The clinical study aims to evaluate the safety and efficacy of umbilical cord blood transfusion in treating bone marrow suppression after chemotherapy in elderly patients with MDS and AML
- Trial name
- NCT07201233
- Testing
- Umbilical cord blood
- Volunteers
- 30 people
- Sponsor
- Shandong Qilu Stem Cells Engineering Co., Ltd.
Myelosuppression, Thoracic Neoplasms
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
This is a prospective observational study designed to observe and evaluate the safety and efficacy of mecapegfilgrastim in the treatment of moderate-to-severe myelosuppression associated with concurrent chemoradiotherapy.
- Conditions
- Myelosuppression, Thoracic Neoplasms, Chemoradiotherapy
- Trial name
- ANC-IIT-004 (NCT07205536)
- Testing
- Mecapegfilgrastim injection, Oral or short-acting granulocyte-stimulating agents
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Affiliated Hospital of Nantong University
Ewing Sarcoma, Myelosuppression
A Prospective, Randomized, Controlled Clinical Study on the Prevention of Chemotherapy Related Myelosuppression in Patients with Ewing's Sarcoma Using Trilaciclib
This study is a prospective, open label, randomized controlled clinical trial aimed at patients with Ewing's sarcoma who have not received systematic anti-tumor treatment in the past.
- Trial name
- NCT06699472
- Testing
- Chemotherapy, Trilaciclib Injection [Cosela]
- Where
- China
- Volunteers
- 22 people
- Sponsor
- Fudan University
ESCC
Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma
Clinical data of patients with synchronous radiotherapy for esophageal cancer in the Department of Radiology of Jiangsu Provincial People's Hospital were collected.
- Trial name
- COSELA (NCT06698692)
- Testing
- Trilaciclib Injection [Cosela]
- Where
- China
- Volunteers
- 200 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Lung Cancer, Small-cell Lung Cancer
Study of Trilaciclib and Lurbinectidin
Lung cancer is by far the leading cause of cancer death among both men and women worldwide and the second most common cancer in terms of new cases. Small cell lung cancer (SCLC) is the deadliest form of lung cancer.
- Trial name
- NCT05578326
- Testing
- Trilaciclib, Lurbinectedin
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-small Cell Lung Cancer
the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib
This study is a single arm, exploratory clinical study aimed at evaluating the efficacy and safety of tralazili before chemotherapy in patients with NSCLC.After pathological diagnosis of non-small cell lung cancer(NSCLC), 40…
- Trial name
- NCT06370416
- Testing
- Trilaciclib
- Where
- China
- Volunteers
- 41 people
- Sponsor
- Henan Cancer Hospital
Tumor Patients
A Single-arm, Multi-center, Phase II Exploratory Clinical Study to Evaluate the Efficacy and Safety of Trilaciclib in Preventing Myelosuppression Caused by Topoisomerase I Inhibitor Type ADC Drugs
Evaluation of the efficacy and safety of Trilaciclib in preventing myelosuppression caused by topoisomerase I inhibitor type ADC drugs
- Trial name
- Trilaciclib (NCT07736001)
- Testing
- Trilaciclib and Topoisomerase I inhibitor type ADC drugs
- Where
- 2 sites in China
- Volunteers
- 96 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Linezolid, Tuberculosis Multi Drug Resistant Active
Linezolid Tolerance During the BPaL Regimen With Dosage Personalization Based on Therapeutic Drug Monitoring (TDM) During Multidrug-Resistant Tuberculosis Treatment
Multidrug-resistant tuberculosis (MDR-TB) poses a significant challenge to global public health. Globally, the World Health Organization (WHO) estimates the number at 400,000 patients with MDR-TB for 2023.
- Conditions
- Linezolid, Tuberculosis Multi Drug Resistant Active, Therapeutic Drug Monitoring (TDM)
- Trial name
- PLOT-TB (NCT07477119)
- Testing
- Linezolid dose personalization based on TDM
- Where
- Guinea
- Volunteers
- 150 people
- Sponsor
- Marco Schiuma
Breast Cancer, Bone Marrow Suppression
A Randomized, Self-controlled Post-marketing Clinical Study on the Comparison of Shengbai Oral Liquid and Leucogen Tablets in the Treatment of Moderate Neutropenia Caused by Anti-tumor Drugs in Breast Cancer Patients
The subjects were randomly assigned to Group A or Group B in a 1:1 ratio, stratified by early/late stage. Group A: In the first cycle, they took Shengbai Oral Liquid (40 ml, three times a day), and in the second cycle, they took…
- Trial name
- NCT07578064
- Testing
- Group A, Group B
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Hongxia Wang